Flora McErlane
YOU?
Author Swipe
View article: The interplay between pain and disease activity: personal models of pain beliefs and emotional representations in children and young people with juvenile idiopathic arthritis in a UK nationwide prospective inception cohort
The interplay between pain and disease activity: personal models of pain beliefs and emotional representations in children and young people with juvenile idiopathic arthritis in a UK nationwide prospective inception cohort Open
Objectives Juvenile idiopathic arthritis (JIA) is a group of childhood-onset inflammatory rheumatic conditions characterized by pain as one of the most common and distressing symptoms. This cross-sectional study aimed to investigate whethe…
View article: OA36 Embedding quality improvement across paediatric and adolescent rheumatology: the JIA Learn experience
OA36 Embedding quality improvement across paediatric and adolescent rheumatology: the JIA Learn experience Open
Background/Aims Juvenile idiopathic arthritis (JIA) is a relatively common chronic paediatric condition with significant potential for lifelong morbidity. Despite significant advances in medical treatment technologies, a persistent discrep…
View article: E062 Real-world experience of tofacitinib as treatment for juvenile idiopathic arthritis
E062 Real-world experience of tofacitinib as treatment for juvenile idiopathic arthritis Open
Background/Aims In October 2021, the National Institute for Health and Care Excellence (NICE) recommended tofacitinib to treat polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis in cases resistant to at leas…
View article: P100 Working together to improve patient and family experiences of care for children and young people with juvenile idiopathic arthritis attending Newcastle Hospitals
P100 Working together to improve patient and family experiences of care for children and young people with juvenile idiopathic arthritis attending Newcastle Hospitals Open
Background/Aims Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood with significant potential for life-long morbidity. Despite advances in medical treatment options, a persistent discrepancy betwe…
View article: Evaluating Renal Disease in Pediatric‐Onset Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome
Evaluating Renal Disease in Pediatric‐Onset Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome Open
Objective We aimed to study the disease course, outcomes, and predictors of outcome in pediatric‐onset antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) affecting the kidneys. Methods Patients eligible for this study h…
View article: Anti-Sp4 and anti-CCAR1 autoantibodies in UK <i>vs</i> US patients with adult and juvenile-onset anti-TIF1γ-positive myositis
Anti-Sp4 and anti-CCAR1 autoantibodies in UK <i>vs</i> US patients with adult and juvenile-onset anti-TIF1γ-positive myositis Open
Objectives Anti-transcriptional intermediary factor 1γ (TIF1γ) autoantibodies are associated with malignancy in adult-onset idiopathic inflammatory myopathy (IIM) and this risk is attenuated if patients are also positive for anti-specifici…
View article: Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood‐Onset Anti‐Neutrophil Cytoplasmic Antibody‐Associated Vasculitis: An <scp>ARChiVe</scp> Registry Cohort Study
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood‐Onset Anti‐Neutrophil Cytoplasmic Antibody‐Associated Vasculitis: An <span>ARChiVe</span> Registry Cohort Study Open
Objective Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are chronic life‐threatening vasculitides requiring substantial immunotherapy. Adult trials identified rituximab (RTX) as an alternative to cyclophosphamid…
View article: P090 Real-world data on immuno-modulation therapies and body mass index in children and young people with juvenile idiopathic arthritis
P090 Real-world data on immuno-modulation therapies and body mass index in children and young people with juvenile idiopathic arthritis Open
Background/Aims There is some evidence that children and young people (CYP) with Juvenile Idiopathic Arthritis (JIA) who are overweight/obese have less favourable disease control and treatment outcomes. The aim of this study was to investi…
View article: TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients
TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients Open
International audience
View article: Overlap of International League of Associations for Rheumatology and Preliminary Pediatric Rheumatology International Trials Organization Classification Criteria for Nonsystemic Juvenile Idiopathic Arthritis in an Established <scp>UK</scp> Multicentre Inception Cohort
Overlap of International League of Associations for Rheumatology and Preliminary Pediatric Rheumatology International Trials Organization Classification Criteria for Nonsystemic Juvenile Idiopathic Arthritis in an Established <span>UK</span> Multicentre Inception Cohort Open
Objective The goal was to assess the degree of overlap between existing International League of Associations for Rheumatology (ILAR) and preliminary Paediatric Rheumatology International Trials Organisation (PRINTO) classification criteria…
View article: The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis
The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis Open
Objectives Juvenile PsA (JPsA) has varied clinical features that are distinctive from other JIA categories. This study investigates whether such features impact patient-reported and clinical outcomes. Methods Children and young people (CYP…
View article: P093 Clinical outcomes and care quality standards in young adult patients with early inflammatory arthritis: Results from a national cohort
P093 Clinical outcomes and care quality standards in young adult patients with early inflammatory arthritis: Results from a national cohort Open
Background/Aims Emerging adulthood is a unique developmental period between late adolescence and establishment of personal and social identity associated with adulthood. Emerging adult populations may have distinctive experiences of adult …
View article: P49 The Barbara Ansell National Network for Adolescent Rheumatology – 10 years on
P49 The Barbara Ansell National Network for Adolescent Rheumatology – 10 years on Open
Introduction/Background Over the last 10 years since BANNAR was established, there has been increasing awareness of the specific age and developmental needs of adolescents and young adults (AYA) with rheumatic disease. The aim of this stud…
View article: 1413 Healthcare transition for young people across the North-East and North Cumbria: scoping exercise against national standards
1413 Healthcare transition for young people across the North-East and North Cumbria: scoping exercise against national standards Open
Aims The transition from childhood to adulthood is a time of great change, emotionally and physically and poses specific challenges in young people (YP) with long-term health conditions. Poorly planned transition of care to adult services …
View article: Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE Open
Objectives Juvenile-onset systemic lupus erythematosus (jSLE) affects 15–20% of lupus patients. Clinical heterogeneity between racial groups, age groups and individual patients suggests variable pathophysiology. This study aimed to identif…
View article: P012 Cross-specialty audit of Infliximab prescribing at the Great North Children’s Hospital (GNCH)
P012 Cross-specialty audit of Infliximab prescribing at the Great North Children’s Hospital (GNCH) Open
Background/Aims Infliximab is an anti-TNF biologic licensed for use in children and young people (CYP) with juvenile idiopathic arthritis (JIA) uncontrolled by methotrexate and children with inflammatory bowel disease uncontrolled by thiop…
View article: Quality Improvement in Juvenile Idiopathic Arthritis: a Mixed-methods Implementation Pilot of the CAPTURE-JIA Dataset
Quality Improvement in Juvenile Idiopathic Arthritis: a Mixed-methods Implementation Pilot of the CAPTURE-JIA Dataset Open
Background A significant proportion of children and young people with juvenile idiopathic arthritis (JIA) do not achieve inactive disease during the first two years following diagnosis. Refinements to clinical care pathways have the potent…
View article: No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA
No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA Open
Objectives The clinical progression of JIA is unpredictable. Knowing who will develop severe disease could facilitate rapid intensification of therapies. We use genetic variants conferring susceptibility to JIA to predict disease outcome m…
View article: Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study
Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study Open
Introduction Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease with significant morbidity and mortality. Neuropsychiatric (NP) involvement is a severe complication, encompassing a heterogeneous ra…
View article: Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma
Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma Open
Background Evidence is lacking for safe and effective treatments for juvenile localised scleroderma (JLS). Methotrexate (MTX) is commonly used first line and mycophenolate mofetil (MMF) second line, despite a limited evidence base. A head …
View article: Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK
Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK Open
Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease. Patients diagnosed with juvenile-onset SLE (jSLE), when compared to individuals with adult-onset SLE, develop more severe organ involvement, increased diseas…
View article: JLS Elicitation Extended data.pdf
JLS Elicitation Extended data.pdf Open
Extended methodology from publication on AMRC of Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised SclerodermaSpecifically:Appendix S1 Participants in prior elicitation meeti…
View article: Wearable technologies for children with chronic illness: A Proof-of-Concept Study
Wearable technologies for children with chronic illness: A Proof-of-Concept Study Open
Objective To determine the feasibility of wearable technologies in physical activity assessment in three paediatric diseases, namely Niemann-Pick C (NP-C), Juvenile Idiopathic Arthritis (JIA) and Duchenne Muscular Dystrophy (DMD). Design P…
View article: G104(P) CRIT: children receiving immunosuppressive therapy: a cross-speciality review of practice at a tertiary children’s hospital
G104(P) CRIT: children receiving immunosuppressive therapy: a cross-speciality review of practice at a tertiary children’s hospital Open
Aims Immunosuppression has become integral to the management of a wide range of childhood illness. Although total numbers of children and young people (CYP) on immunosuppression is unknown, they are thought to be increasing. Multiple paedi…
View article: Validation of novel patient-centred juvenile idiopathic arthritis-specific patient-reported outcome and experience measures (PROMs/PREMs)
Validation of novel patient-centred juvenile idiopathic arthritis-specific patient-reported outcome and experience measures (PROMs/PREMs) Open
Background: Measuring the outcomes that matter to children and young people (CYP) with juvenile idiopathic arthritis (JIA), is a necessary precursor to patient-centred improvements in quality of clinical care. We present a two-centre valid…